These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 22910956)

  • 1. ACP Journal Club: review: varenicline for tobacco cessation does not increase CV serious adverse events.
    Krebs P; Sherman SE
    Ann Intern Med; 2012 Aug; 157(4):JC2-2. PubMed ID: 22910956
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Review: Varenicline increases risk for serious adverse cardiovascular events in tobacco users.
    Brophy JM
    Ann Intern Med; 2011 Oct; 155(8):JC4-5. PubMed ID: 22007064
    [No Abstract]   [Full Text] [Related]  

  • 3. ACP Journal Club. Review: statins decrease mortality and major CV events in adults with CKD not receiving dialysis.
    Ramesh Prasad GV
    Ann Intern Med; 2012 Nov; 157(10):JC5-4. PubMed ID: 23165680
    [No Abstract]   [Full Text] [Related]  

  • 4. ACP Journal Club. Review: ACE-Is or ARBs reduce adverse CV outcomes regardless of baseline systolic blood pressure.
    Singh V
    Ann Intern Med; 2012 Jul; 157(2):JC2-8. PubMed ID: 22801699
    [No Abstract]   [Full Text] [Related]  

  • 5. ACP Journal Club. Adding omeprazole to clopidogrel reduced GI events and did not increase CV events.
    Chow CK
    Ann Intern Med; 2011 Mar; 154(6):JC3-7. PubMed ID: 21403070
    [No Abstract]   [Full Text] [Related]  

  • 6. ACP Journal Club: review: dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes.
    Chatterjee S; Chatterjee S
    Ann Intern Med; 2013 Apr; 158(8):JC8. PubMed ID: 23588773
    [No Abstract]   [Full Text] [Related]  

  • 7. ACP Journal Club. Review: lipid-lowering drugs decrease all-cause and cardiac mortality and CV events in CKD.
    Ramesh Prasad GV
    Ann Intern Med; 2012 Nov; 157(10):JC5-5. PubMed ID: 23165681
    [No Abstract]   [Full Text] [Related]  

  • 8. ACP Journal Club: Review: Low BP targets do not reduce mortality or CV events in hypertension.
    McAlister FA
    Ann Intern Med; 2009 Nov; 151(10):JC5-6-7. PubMed ID: 19920264
    [No Abstract]   [Full Text] [Related]  

  • 9. ACP Journal Club. Review: oral phosphodiesterase 4 inhibitors reduce exacerbations but increase adverse events in COPD.
    Ram FS
    Ann Intern Med; 2011 Sep; 155(6):JC3-2. PubMed ID: 21930839
    [No Abstract]   [Full Text] [Related]  

  • 10. ACP Journal Club. Valsartan reduced diabetes but not CV events in patients with impaired glucose tolerance and CV risk factors.
    Ann Intern Med; 2010 Jun; 152(12):JC6-9. PubMed ID: 20547903
    [No Abstract]   [Full Text] [Related]  

  • 11. ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.
    Farkouh M
    Ann Intern Med; 2010 Jun; 152(12):JC6-10. PubMed ID: 20547892
    [No Abstract]   [Full Text] [Related]  

  • 12. ACP Journal Club. Glargine did not reduce CV events more than standard care in patients with dysglycemia.
    Lader E
    Ann Intern Med; 2012 Sep; 157(6):JC3-10, JC3-11. PubMed ID: 22986402
    [No Abstract]   [Full Text] [Related]  

  • 13. ACP Journal Club. Review: Androgen deprivation therapy does not increase CV mortality in prostate cancer.
    Canfield SE; Dahm P
    Ann Intern Med; 2012 Apr; 156(8):JC4-04, JC4-05. PubMed ID: 22508744
    [No Abstract]   [Full Text] [Related]  

  • 14. ACP Journal Club. Review: Aspirin does not reduce CV events but may reduce nonfatal stroke in peripheral artery disease.
    Mukherjee D
    Ann Intern Med; 2009 Sep; 151(6):JC3-5, JC3-4. PubMed ID: 19755351
    [No Abstract]   [Full Text] [Related]  

  • 15. ACP Journal Club. Review: Intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes.
    Lipscombe LL
    Ann Intern Med; 2009 Sep; 151(6):JC3-6. PubMed ID: 19755352
    [No Abstract]   [Full Text] [Related]  

  • 16. ACP Journal Club. Review: lithium is associated with adverse events in patients with mood disorders.
    Preda A
    Ann Intern Med; 2012 Jul; 157(2):JC2-10. PubMed ID: 22801701
    [No Abstract]   [Full Text] [Related]  

  • 17. ACP Journal Club. Review: Nicotine gum and varenicline, but not behavioral interventions, reduce relapse in persons who have stopped smoking.
    Bentz CJ
    Ann Intern Med; 2009 Jul; 151(2):JC1-11. PubMed ID: 19620155
    [No Abstract]   [Full Text] [Related]  

  • 18. ACP Journal Club. Review: biologic agents increase short-term risk for some adverse events in conditions other than HIV or AIDS.
    Schattner A
    Ann Intern Med; 2012 May; 156(10):JC5-9. PubMed ID: 22586027
    [No Abstract]   [Full Text] [Related]  

  • 19. ACP Journal Club. Daily n-3 fatty acid supplements did not reduce CV events in high-risk patients with dysglycemia.
    Lader E
    Ann Intern Med; 2012 Sep; 157(6):JC3-11. PubMed ID: 22986403
    [No Abstract]   [Full Text] [Related]  

  • 20. ACP Journal Club. Daily multivitamin supplements did not reduce risk for major CV events over > 10 years in men.
    Fairfield KM
    Ann Intern Med; 2013 Feb; 158(4):JC8. PubMed ID: 23420255
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.